IDEXX Laboratories, Inc. $IDXX Shares Sold by RFG Advisory LLC

RFG Advisory LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 49.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,332 shares of the company’s stock after selling 1,299 shares during the period. RFG Advisory LLC’s holdings in IDEXX Laboratories were worth $748,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of IDXX. Elyxium Wealth LLC acquired a new position in IDEXX Laboratories during the fourth quarter valued at $3,666,459,000. J. Stern & Co. LLP lifted its position in shares of IDEXX Laboratories by 23,694.7% during the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after buying an additional 2,642,200 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of IDEXX Laboratories by 63,503.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after purchasing an additional 1,442,174 shares during the period. Wellington Management Group LLP boosted its holdings in IDEXX Laboratories by 318.1% in the 4th quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after buying an additional 592,834 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $332,265,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IDXX has been the subject of a number of recent research reports. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday. Stifel Nicolaus cut their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Finally, UBS Group dropped their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $551.50 on Monday. The firm has a 50 day simple moving average of $558.79 and a 200-day simple moving average of $614.13. The company has a market capitalization of $43.50 billion, a PE ratio of 40.61, a P/E/G ratio of 3.02 and a beta of 1.56. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the business earned $2.91 EPS. The business’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.